Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cell Therapeutics Inc    

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Cell Therapeutics Inc : Five Star Equities Issues New Research Reports on CTIC, PACB, SEED and STML

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/21/2014 | 02:50pm CEST

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Cell Therapeutics Inc. (NASDAQ: CTIC) shares jumped 13.75 percent to close at $3.64 a share Friday. The stock traded between $3.40 and $3.79 on volume 13.56 million shares traded. Earlier this month, the company received notification from the FDA that the partial clinical hold on Tosedostat has been removed and all studies underway may continue. Shares of Cell Therapeutics have gained approximately 140.0 percent in the past year.

Get more information on Cell Therapeutics free access to the in-depth equity report at:
www.FiveStarEquities.com/CTIC

Pacific Biosciences of California (NASDAQ: PACB) shares spiked 14.44 percent to close at $6.50 a share Friday. The stock traded between $5.65 and $6.97 on volume 2.70 million shares traded. The company is scheduled to release Fourth Quarter and Year End 2013 results on Tuesday, February 4th. Shares of Pacific Biosciences of California have gained approximately 160.0 percent in the past year.

Get more information on Pacific Biosciences and free access to the in-depth equity report at:
www.FiveStarEquities.com/PACB

Origin Agritech Ltd. (NASDAQ: SEED) shares surged 18.81 percent to close at $2.40 a share Friday. The stock traded between $2.03 and $2.55 on volume of 2.70 million shares traded. The company recently reported an operating income of RMB18.16 million for the fiscal year 2013, compared to an operating loss of RMB (3.47) million a year ago. Shares of Origin Agritech have gained approximately 56.0 percent in the past year.

Get more information on Origin Agritech and free access to the in-depth equity report at:
www.FiveStarEquities.com/SEED

Stemline Therapeutics Inc. (NASDAQ: STML) shares soared 39.50 percent to close at $30.44 a share Friday. The stock traded between $22.00 and $30.45 on volume 1.40 million shares traded. Ivan Bergstein, M.D., Stemline's CEO, presented at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014. Shares of Stemline Therapeutics have gained approximately 150.0 percent in the past year.

Get more information on Stemline Therapeutics and free access to the in-depth equity report at:
www.FiveStarEquities.com/STML

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com


© Accesswire 2014
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELL THERAPEUTICS INC
08/11 REGENERON PHARMACEUTICALS : and Adicet Bio Announce Strategic Collaboration to D..
08/11 CTI BIOPHARMA : Reports Second Quarter 2016 Financial Results
08/05 CTI BIOPHARMA : reports 2Q loss
08/04 CTI BIOPHARMA : Management's Discussion and Analysis of Financial Condition and ..
08/04 CTI BIOPHARMA CORP : Results of Operations and Financial Condition, Financial St..
07/28 CTI BIOPHARMA CORP : Results of Operations and Financial Condition, Regulation F..
06/30 CTI BIOPHARMA CORP : Results of Operations and Financial Condition, Regulation F..
06/16 CTI BIOPHARMA : Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO A..
05/31 CTI BIOPHARMA CORP : Results of Operations and Financial Condition, Regulation F..
05/19 CTI BIOPHARMA : Reports First Quarter 2016 Financial Results
More news
Sector news : Biotechnology & Medical Research - NEC
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Financials ($)
Sales 2016 45,2 M
EBIT 2016 -52,8 M
Net income 2016 -53,8 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 2,19x
Capi. / Sales 2017 16,8x
Capitalization 99,0 M
More Financials
Technical analysis trends CELL THERAPEUTICS...
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 3
Average target price 1,92 $
Spread / Average Target 448%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
James A. Bianco President, Chief Executive Officer & Director
Phillip M. Nudelman Chairman
Lou A. Bianco Secretary, Executive VP-Finance & Administration
Jack W. Singer Director, Chief Scientific & Medical Officer
Mary O'Neil Mundinger Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELL THERAPEUTICS INC99
INCYTE CORPORATION-25.27%15 236
CELLTRION, INC.--.--%11 367
LONZA GROUP AG14.78%10 130
QUINTILES TRANSNATIONA..10.24%8 968
ALKERMES PLC-43.94%6 744
More Results